Disrupting the PTENα/β-WDR5 interaction by point mutations of the key interacting residues attenuates these effects, which indicates that novel therapies for cancer treatment could be potentially developed by targeting the interaction between PTENα/β and WDR5. The gene discussed is WDR5; the disease is cancer.